Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
27,461
archived clinical trials in
Hematology

Magnetic Resonance Imaging in Measuring the Effect of Cabozantinib in Patients With Castrate Resistant Prostate Cancer
A Phase II Study of MRI Based Functional Imaging for the Evaluation of Bone Metastasis in Men With Castrate Resistant Prostate Cancer Receiving XL184
Status: Enrolling
Updated:  12/31/1969
University of Chicago
mi
from
Chicago, IL
Magnetic Resonance Imaging in Measuring the Effect of Cabozantinib in Patients With Castrate Resistant Prostate Cancer
A Phase II Study of MRI Based Functional Imaging for the Evaluation of Bone Metastasis in Men With Castrate Resistant Prostate Cancer Receiving XL184
Status: Enrolling
Updated: 12/31/1969
University of Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials
A Study of Tabalumab (LY2127399) in Participants With Previously Treated Multiple Myeloma (MM)
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Tabalumab in Combination With Bortezomib and Dexamethasone in Patients With Previously Treated Multiple Myeloma
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Indianapolis, IN
A Study of Tabalumab (LY2127399) in Participants With Previously Treated Multiple Myeloma (MM)
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Tabalumab in Combination With Bortezomib and Dexamethasone in Patients With Previously Treated Multiple Myeloma
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Indianapolis, IN
Click here to add this to my saved trials
A Study of Tabalumab (LY2127399) in Participants With Previously Treated Multiple Myeloma (MM)
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Tabalumab in Combination With Bortezomib and Dexamethasone in Patients With Previously Treated Multiple Myeloma
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Iowa City, IA
A Study of Tabalumab (LY2127399) in Participants With Previously Treated Multiple Myeloma (MM)
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Tabalumab in Combination With Bortezomib and Dexamethasone in Patients With Previously Treated Multiple Myeloma
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Iowa City, IA
Click here to add this to my saved trials
A Study of Tabalumab (LY2127399) in Participants With Previously Treated Multiple Myeloma (MM)
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Tabalumab in Combination With Bortezomib and Dexamethasone in Patients With Previously Treated Multiple Myeloma
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Tucson, AZ
A Study of Tabalumab (LY2127399) in Participants With Previously Treated Multiple Myeloma (MM)
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Tabalumab in Combination With Bortezomib and Dexamethasone in Patients With Previously Treated Multiple Myeloma
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Tucson, AZ
Click here to add this to my saved trials
A Study of Tabalumab (LY2127399) in Participants With Previously Treated Multiple Myeloma (MM)
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Tabalumab in Combination With Bortezomib and Dexamethasone in Patients With Previously Treated Multiple Myeloma
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Fullerton, CA
A Study of Tabalumab (LY2127399) in Participants With Previously Treated Multiple Myeloma (MM)
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Tabalumab in Combination With Bortezomib and Dexamethasone in Patients With Previously Treated Multiple Myeloma
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Fullerton, CA
Click here to add this to my saved trials
A Study of Tabalumab (LY2127399) in Participants With Previously Treated Multiple Myeloma (MM)
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Tabalumab in Combination With Bortezomib and Dexamethasone in Patients With Previously Treated Multiple Myeloma
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Los Angeles, CA
A Study of Tabalumab (LY2127399) in Participants With Previously Treated Multiple Myeloma (MM)
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Tabalumab in Combination With Bortezomib and Dexamethasone in Patients With Previously Treated Multiple Myeloma
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Study of Tabalumab (LY2127399) in Participants With Previously Treated Multiple Myeloma (MM)
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Tabalumab in Combination With Bortezomib and Dexamethasone in Patients With Previously Treated Multiple Myeloma
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Santa Barbara, CA
A Study of Tabalumab (LY2127399) in Participants With Previously Treated Multiple Myeloma (MM)
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Tabalumab in Combination With Bortezomib and Dexamethasone in Patients With Previously Treated Multiple Myeloma
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Santa Barbara, CA
Click here to add this to my saved trials
A Study of Tabalumab (LY2127399) in Participants With Previously Treated Multiple Myeloma (MM)
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Tabalumab in Combination With Bortezomib and Dexamethasone in Patients With Previously Treated Multiple Myeloma
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Grand Junction, CO
A Study of Tabalumab (LY2127399) in Participants With Previously Treated Multiple Myeloma (MM)
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Tabalumab in Combination With Bortezomib and Dexamethasone in Patients With Previously Treated Multiple Myeloma
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Grand Junction, CO
Click here to add this to my saved trials
A Study of Tabalumab (LY2127399) in Participants With Previously Treated Multiple Myeloma (MM)
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Tabalumab in Combination With Bortezomib and Dexamethasone in Patients With Previously Treated Multiple Myeloma
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Atlanta, GA
A Study of Tabalumab (LY2127399) in Participants With Previously Treated Multiple Myeloma (MM)
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Tabalumab in Combination With Bortezomib and Dexamethasone in Patients With Previously Treated Multiple Myeloma
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Atlanta, GA
Click here to add this to my saved trials
A Study of Tabalumab (LY2127399) in Participants With Previously Treated Multiple Myeloma (MM)
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Tabalumab in Combination With Bortezomib and Dexamethasone in Patients With Previously Treated Multiple Myeloma
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Cedar Rapids, IA
A Study of Tabalumab (LY2127399) in Participants With Previously Treated Multiple Myeloma (MM)
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Tabalumab in Combination With Bortezomib and Dexamethasone in Patients With Previously Treated Multiple Myeloma
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Cedar Rapids, IA
Click here to add this to my saved trials
A Study of Tabalumab (LY2127399) in Participants With Previously Treated Multiple Myeloma (MM)
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Tabalumab in Combination With Bortezomib and Dexamethasone in Patients With Previously Treated Multiple Myeloma
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Ashland, KY
A Study of Tabalumab (LY2127399) in Participants With Previously Treated Multiple Myeloma (MM)
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Tabalumab in Combination With Bortezomib and Dexamethasone in Patients With Previously Treated Multiple Myeloma
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Ashland, KY
Click here to add this to my saved trials
A Study of Tabalumab (LY2127399) in Participants With Previously Treated Multiple Myeloma (MM)
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Tabalumab in Combination With Bortezomib and Dexamethasone in Patients With Previously Treated Multiple Myeloma
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Boston, MA
A Study of Tabalumab (LY2127399) in Participants With Previously Treated Multiple Myeloma (MM)
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Tabalumab in Combination With Bortezomib and Dexamethasone in Patients With Previously Treated Multiple Myeloma
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Boston, MA
Click here to add this to my saved trials
A Study of Tabalumab (LY2127399) in Participants With Previously Treated Multiple Myeloma (MM)
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Tabalumab in Combination With Bortezomib and Dexamethasone in Patients With Previously Treated Multiple Myeloma
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Omaha, NE
A Study of Tabalumab (LY2127399) in Participants With Previously Treated Multiple Myeloma (MM)
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Tabalumab in Combination With Bortezomib and Dexamethasone in Patients With Previously Treated Multiple Myeloma
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Omaha, NE
Click here to add this to my saved trials
A Study of Tabalumab (LY2127399) in Participants With Previously Treated Multiple Myeloma (MM)
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Tabalumab in Combination With Bortezomib and Dexamethasone in Patients With Previously Treated Multiple Myeloma
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Albuquerque, NM
A Study of Tabalumab (LY2127399) in Participants With Previously Treated Multiple Myeloma (MM)
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Tabalumab in Combination With Bortezomib and Dexamethasone in Patients With Previously Treated Multiple Myeloma
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Albuquerque, NM
Click here to add this to my saved trials
A Study of Tabalumab (LY2127399) in Participants With Previously Treated Multiple Myeloma (MM)
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Tabalumab in Combination With Bortezomib and Dexamethasone in Patients With Previously Treated Multiple Myeloma
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Salt Lake City, UT
A Study of Tabalumab (LY2127399) in Participants With Previously Treated Multiple Myeloma (MM)
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Tabalumab in Combination With Bortezomib and Dexamethasone in Patients With Previously Treated Multiple Myeloma
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
A Study of Tabalumab (LY2127399) in Participants With Previously Treated Multiple Myeloma (MM)
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Tabalumab in Combination With Bortezomib and Dexamethasone in Patients With Previously Treated Multiple Myeloma
Status: Enrolling
Updated:  12/31/1969
mi
from
Campinas,
A Study of Tabalumab (LY2127399) in Participants With Previously Treated Multiple Myeloma (MM)
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Tabalumab in Combination With Bortezomib and Dexamethasone in Patients With Previously Treated Multiple Myeloma
Status: Enrolling
Updated: 12/31/1969
mi
from
Campinas,
Click here to add this to my saved trials
Dasatinib for Modulating Immune System After Autologous Stem Cell Transplants for Multiple Myeloma, Non-Hodgkin, or Hodgkin Lymphoma
Phase I/II Study of Dasatinib in Recipients of Autologous Stem Cell Transplantation for Hematologic Malignancies.
Status: Enrolling
Updated:  12/31/1969
Barbara Ann Karmanos Cancer Institute
mi
from
Detroit, MI
Dasatinib for Modulating Immune System After Autologous Stem Cell Transplants for Multiple Myeloma, Non-Hodgkin, or Hodgkin Lymphoma
Phase I/II Study of Dasatinib in Recipients of Autologous Stem Cell Transplantation for Hematologic Malignancies.
Status: Enrolling
Updated: 12/31/1969
Barbara Ann Karmanos Cancer Institute
mi
from
Detroit, MI
Click here to add this to my saved trials
Ibrutinib (PCI-32765) in Waldenstrom's Macroglobulinemia
Phase 2 Study of Bruton's Tyrosine Kinase (Btk) Inhibitor, Ibrutinib (PCI-32765), in Waldenstrom's Macroglobulinemia
Status: Enrolling
Updated:  12/31/1969
Dana-Farber Cancer Institute
mi
from
Boston, MA
Ibrutinib (PCI-32765) in Waldenstrom's Macroglobulinemia
Phase 2 Study of Bruton's Tyrosine Kinase (Btk) Inhibitor, Ibrutinib (PCI-32765), in Waldenstrom's Macroglobulinemia
Status: Enrolling
Updated: 12/31/1969
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Ibrutinib (PCI-32765) in Waldenstrom's Macroglobulinemia
Phase 2 Study of Bruton's Tyrosine Kinase (Btk) Inhibitor, Ibrutinib (PCI-32765), in Waldenstrom's Macroglobulinemia
Status: Enrolling
Updated:  12/31/1969
Brigham and Women's Hosp
mi
from
Boston, MA
Ibrutinib (PCI-32765) in Waldenstrom's Macroglobulinemia
Phase 2 Study of Bruton's Tyrosine Kinase (Btk) Inhibitor, Ibrutinib (PCI-32765), in Waldenstrom's Macroglobulinemia
Status: Enrolling
Updated: 12/31/1969
Brigham and Women's Hosp
mi
from
Boston, MA
Click here to add this to my saved trials
Ibrutinib (PCI-32765) in Waldenstrom's Macroglobulinemia
Phase 2 Study of Bruton's Tyrosine Kinase (Btk) Inhibitor, Ibrutinib (PCI-32765), in Waldenstrom's Macroglobulinemia
Status: Enrolling
Updated:  12/31/1969
Stanford University
mi
from
Palo Alto, CA
Ibrutinib (PCI-32765) in Waldenstrom's Macroglobulinemia
Phase 2 Study of Bruton's Tyrosine Kinase (Btk) Inhibitor, Ibrutinib (PCI-32765), in Waldenstrom's Macroglobulinemia
Status: Enrolling
Updated: 12/31/1969
Stanford University
mi
from
Palo Alto, CA
Click here to add this to my saved trials
Ibrutinib (PCI-32765) in Waldenstrom's Macroglobulinemia
Phase 2 Study of Bruton's Tyrosine Kinase (Btk) Inhibitor, Ibrutinib (PCI-32765), in Waldenstrom's Macroglobulinemia
Status: Enrolling
Updated:  12/31/1969
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Ibrutinib (PCI-32765) in Waldenstrom's Macroglobulinemia
Phase 2 Study of Bruton's Tyrosine Kinase (Btk) Inhibitor, Ibrutinib (PCI-32765), in Waldenstrom's Macroglobulinemia
Status: Enrolling
Updated: 12/31/1969
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Hemophilia B Gene Therapy With AAV8 Vector
A Phase 1 Safety Study in Subjects With Severe Hemophilia B (Factor IX Deficiency) Using a Single-Stranded, Adeno-Associated Pseudotype 8 Viral Vector to Deliver the Gene for Human Factor IX
Status: Enrolling
Updated:  12/31/1969
Children's Hospital of Philadelphia
mi
from
Philadelphia, PA
Hemophilia B Gene Therapy With AAV8 Vector
A Phase 1 Safety Study in Subjects With Severe Hemophilia B (Factor IX Deficiency) Using a Single-Stranded, Adeno-Associated Pseudotype 8 Viral Vector to Deliver the Gene for Human Factor IX
Status: Enrolling
Updated: 12/31/1969
Children's Hospital of Philadelphia
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Hemophilia B Gene Therapy With AAV8 Vector
A Phase 1 Safety Study in Subjects With Severe Hemophilia B (Factor IX Deficiency) Using a Single-Stranded, Adeno-Associated Pseudotype 8 Viral Vector to Deliver the Gene for Human Factor IX
Status: Enrolling
Updated:  12/31/1969
University of Pittsburgh
mi
from
Pittsburgh, PA
Hemophilia B Gene Therapy With AAV8 Vector
A Phase 1 Safety Study in Subjects With Severe Hemophilia B (Factor IX Deficiency) Using a Single-Stranded, Adeno-Associated Pseudotype 8 Viral Vector to Deliver the Gene for Human Factor IX
Status: Enrolling
Updated: 12/31/1969
University of Pittsburgh
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Hemophilia B Gene Therapy With AAV8 Vector
A Phase 1 Safety Study in Subjects With Severe Hemophilia B (Factor IX Deficiency) Using a Single-Stranded, Adeno-Associated Pseudotype 8 Viral Vector to Deliver the Gene for Human Factor IX
Status: Enrolling
Updated:  12/31/1969
Royal Prince Alfred Hospital
mi
from
Camperdown,
Hemophilia B Gene Therapy With AAV8 Vector
A Phase 1 Safety Study in Subjects With Severe Hemophilia B (Factor IX Deficiency) Using a Single-Stranded, Adeno-Associated Pseudotype 8 Viral Vector to Deliver the Gene for Human Factor IX
Status: Enrolling
Updated: 12/31/1969
Royal Prince Alfred Hospital
mi
from
Camperdown,
Click here to add this to my saved trials
Decitabine, Cytarabine, and Daunorubicin Hydrochloride in Treating Patients With Acute Myeloid Leukemia
Randomized Phase II Study of Epigenetic Priming Using Decitabine With Induction Chemotherapy in Patients With Acute Myelogenous Leukemia (AML)
Status: Enrolling
Updated:  12/31/1969
Lafayette Family Cancer Center-EMMC
mi
from
Brewer, ME
Decitabine, Cytarabine, and Daunorubicin Hydrochloride in Treating Patients With Acute Myeloid Leukemia
Randomized Phase II Study of Epigenetic Priming Using Decitabine With Induction Chemotherapy in Patients With Acute Myelogenous Leukemia (AML)
Status: Enrolling
Updated: 12/31/1969
Lafayette Family Cancer Center-EMMC
mi
from
Brewer, ME
Click here to add this to my saved trials
Decitabine, Cytarabine, and Daunorubicin Hydrochloride in Treating Patients With Acute Myeloid Leukemia
Randomized Phase II Study of Epigenetic Priming Using Decitabine With Induction Chemotherapy in Patients With Acute Myelogenous Leukemia (AML)
Status: Enrolling
Updated:  12/31/1969
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Decitabine, Cytarabine, and Daunorubicin Hydrochloride in Treating Patients With Acute Myeloid Leukemia
Randomized Phase II Study of Epigenetic Priming Using Decitabine With Induction Chemotherapy in Patients With Acute Myelogenous Leukemia (AML)
Status: Enrolling
Updated: 12/31/1969
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Click here to add this to my saved trials
Decitabine, Cytarabine, and Daunorubicin Hydrochloride in Treating Patients With Acute Myeloid Leukemia
Randomized Phase II Study of Epigenetic Priming Using Decitabine With Induction Chemotherapy in Patients With Acute Myelogenous Leukemia (AML)
Status: Enrolling
Updated:  12/31/1969
Case Western Reserve Univ
mi
from
Cleveland, OH
Decitabine, Cytarabine, and Daunorubicin Hydrochloride in Treating Patients With Acute Myeloid Leukemia
Randomized Phase II Study of Epigenetic Priming Using Decitabine With Induction Chemotherapy in Patients With Acute Myelogenous Leukemia (AML)
Status: Enrolling
Updated: 12/31/1969
Case Western Reserve Univ
mi
from
Cleveland, OH
Click here to add this to my saved trials
Decitabine, Cytarabine, and Daunorubicin Hydrochloride in Treating Patients With Acute Myeloid Leukemia
Randomized Phase II Study of Epigenetic Priming Using Decitabine With Induction Chemotherapy in Patients With Acute Myelogenous Leukemia (AML)
Status: Enrolling
Updated:  12/31/1969
Ohio State University Comprehensive Cancer Center
mi
from
Columbus, OH
Decitabine, Cytarabine, and Daunorubicin Hydrochloride in Treating Patients With Acute Myeloid Leukemia
Randomized Phase II Study of Epigenetic Priming Using Decitabine With Induction Chemotherapy in Patients With Acute Myelogenous Leukemia (AML)
Status: Enrolling
Updated: 12/31/1969
Ohio State University Comprehensive Cancer Center
mi
from
Columbus, OH
Click here to add this to my saved trials
Decitabine, Cytarabine, and Daunorubicin Hydrochloride in Treating Patients With Acute Myeloid Leukemia
Randomized Phase II Study of Epigenetic Priming Using Decitabine With Induction Chemotherapy in Patients With Acute Myelogenous Leukemia (AML)
Status: Enrolling
Updated:  12/31/1969
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Decitabine, Cytarabine, and Daunorubicin Hydrochloride in Treating Patients With Acute Myeloid Leukemia
Randomized Phase II Study of Epigenetic Priming Using Decitabine With Induction Chemotherapy in Patients With Acute Myelogenous Leukemia (AML)
Status: Enrolling
Updated: 12/31/1969
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Decitabine, Cytarabine, and Daunorubicin Hydrochloride in Treating Patients With Acute Myeloid Leukemia
Randomized Phase II Study of Epigenetic Priming Using Decitabine With Induction Chemotherapy in Patients With Acute Myelogenous Leukemia (AML)
Status: Enrolling
Updated:  12/31/1969
Montefiore Medical Center-Weiler Hospital
mi
from
Bronx, NY
Decitabine, Cytarabine, and Daunorubicin Hydrochloride in Treating Patients With Acute Myeloid Leukemia
Randomized Phase II Study of Epigenetic Priming Using Decitabine With Induction Chemotherapy in Patients With Acute Myelogenous Leukemia (AML)
Status: Enrolling
Updated: 12/31/1969
Montefiore Medical Center-Weiler Hospital
mi
from
Bronx, NY
Click here to add this to my saved trials
Decitabine, Cytarabine, and Daunorubicin Hydrochloride in Treating Patients With Acute Myeloid Leukemia
Randomized Phase II Study of Epigenetic Priming Using Decitabine With Induction Chemotherapy in Patients With Acute Myelogenous Leukemia (AML)
Status: Enrolling
Updated:  12/31/1969
Montefiore Medical Center - Moses Campus
mi
from
Bronx, NY
Decitabine, Cytarabine, and Daunorubicin Hydrochloride in Treating Patients With Acute Myeloid Leukemia
Randomized Phase II Study of Epigenetic Priming Using Decitabine With Induction Chemotherapy in Patients With Acute Myelogenous Leukemia (AML)
Status: Enrolling
Updated: 12/31/1969
Montefiore Medical Center - Moses Campus
mi
from
Bronx, NY
Click here to add this to my saved trials
Decitabine, Cytarabine, and Daunorubicin Hydrochloride in Treating Patients With Acute Myeloid Leukemia
Randomized Phase II Study of Epigenetic Priming Using Decitabine With Induction Chemotherapy in Patients With Acute Myelogenous Leukemia (AML)
Status: Enrolling
Updated:  12/31/1969
NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center
mi
from
New York, NY
Decitabine, Cytarabine, and Daunorubicin Hydrochloride in Treating Patients With Acute Myeloid Leukemia
Randomized Phase II Study of Epigenetic Priming Using Decitabine With Induction Chemotherapy in Patients With Acute Myelogenous Leukemia (AML)
Status: Enrolling
Updated: 12/31/1969
NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Decitabine, Cytarabine, and Daunorubicin Hydrochloride in Treating Patients With Acute Myeloid Leukemia
Randomized Phase II Study of Epigenetic Priming Using Decitabine With Induction Chemotherapy in Patients With Acute Myelogenous Leukemia (AML)
Status: Enrolling
Updated:  12/31/1969
NYP Weill Cornell Medical Center
mi
from
New York, NY
Decitabine, Cytarabine, and Daunorubicin Hydrochloride in Treating Patients With Acute Myeloid Leukemia
Randomized Phase II Study of Epigenetic Priming Using Decitabine With Induction Chemotherapy in Patients With Acute Myelogenous Leukemia (AML)
Status: Enrolling
Updated: 12/31/1969
NYP Weill Cornell Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
Clofarabine Followed By Lenalidomide for High-Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia
Clofarabine Followed by Lenalidomide for Treatment of High Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia
Status: Enrolling
Updated:  12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Clofarabine Followed By Lenalidomide for High-Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia
Clofarabine Followed by Lenalidomide for Treatment of High Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia
Status: Enrolling
Updated: 12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Donor Cord Blood T-Cell Infusion After Stem Cell Transplant in Treating Patients With Relapsed Hematological Malignancies
Phase I Study of Ex Vivo Expanded Donor Cord Blood T-Lymphocyte Infusion in Post-Transplant Relapsed Patients
Status: Enrolling
Updated:  12/31/1969
M D Anderson Cancer Center
mi
from
Houston, TX
Donor Cord Blood T-Cell Infusion After Stem Cell Transplant in Treating Patients With Relapsed Hematological Malignancies
Phase I Study of Ex Vivo Expanded Donor Cord Blood T-Lymphocyte Infusion in Post-Transplant Relapsed Patients
Status: Enrolling
Updated: 12/31/1969
M D Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Pomalidomide in Combination With Low-Dose Dexamethasone Versus High-Dose Dexamethasone in Subjects With Refractory Multiple Myeloma or Relapsed and Refractory Multiple Myeloma and Companion Study
A Phase 3, Muticenter, Randomized, Open-label Study to Compare the Efficacy and Safety of Pomalidomide in Combination With Low-dose Dexamethasone Versus High-dose Dexamethasone in Subjects With Refractory or Relapsed and Refractory Multiple Myeloma
Status: Enrolling
Updated:  12/31/1969
The Mayo Clinic
mi
from
Rochester, MN
A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Pomalidomide in Combination With Low-Dose Dexamethasone Versus High-Dose Dexamethasone in Subjects With Refractory Multiple Myeloma or Relapsed and Refractory Multiple Myeloma and Companion Study
A Phase 3, Muticenter, Randomized, Open-label Study to Compare the Efficacy and Safety of Pomalidomide in Combination With Low-dose Dexamethasone Versus High-dose Dexamethasone in Subjects With Refractory or Relapsed and Refractory Multiple Myeloma
Status: Enrolling
Updated: 12/31/1969
The Mayo Clinic
mi
from
Rochester, MN
Click here to add this to my saved trials
A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Pomalidomide in Combination With Low-Dose Dexamethasone Versus High-Dose Dexamethasone in Subjects With Refractory Multiple Myeloma or Relapsed and Refractory Multiple Myeloma and Companion Study
A Phase 3, Muticenter, Randomized, Open-label Study to Compare the Efficacy and Safety of Pomalidomide in Combination With Low-dose Dexamethasone Versus High-dose Dexamethasone in Subjects With Refractory or Relapsed and Refractory Multiple Myeloma
Status: Enrolling
Updated:  12/31/1969
Royal Adelaide Hospital
mi
from
Adelaide,
A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Pomalidomide in Combination With Low-Dose Dexamethasone Versus High-Dose Dexamethasone in Subjects With Refractory Multiple Myeloma or Relapsed and Refractory Multiple Myeloma and Companion Study
A Phase 3, Muticenter, Randomized, Open-label Study to Compare the Efficacy and Safety of Pomalidomide in Combination With Low-dose Dexamethasone Versus High-dose Dexamethasone in Subjects With Refractory or Relapsed and Refractory Multiple Myeloma
Status: Enrolling
Updated: 12/31/1969
Royal Adelaide Hospital
mi
from
Adelaide,
Click here to add this to my saved trials
Phase 3 Study With Carfilzomib and Dexamethasone Versus Bortezomib and Dexamethasone for Relapsed Multiple Myeloma Patients
A Randomized, Open-label, Phase 3 Study of Carfilzomib Plus Dexamethasone vs. Bortezomib Plus Dexamethasone in Patients With Relapsed Multiple Myeloma
Status: Enrolling
Updated:  12/31/1969
Providence St. Joseph Medical Center
mi
from
Burbank, CA
Phase 3 Study With Carfilzomib and Dexamethasone Versus Bortezomib and Dexamethasone for Relapsed Multiple Myeloma Patients
A Randomized, Open-label, Phase 3 Study of Carfilzomib Plus Dexamethasone vs. Bortezomib Plus Dexamethasone in Patients With Relapsed Multiple Myeloma
Status: Enrolling
Updated: 12/31/1969
Providence St. Joseph Medical Center
mi
from
Burbank, CA
Click here to add this to my saved trials
Phase 3 Study With Carfilzomib and Dexamethasone Versus Bortezomib and Dexamethasone for Relapsed Multiple Myeloma Patients
A Randomized, Open-label, Phase 3 Study of Carfilzomib Plus Dexamethasone vs. Bortezomib Plus Dexamethasone in Patients With Relapsed Multiple Myeloma
Status: Enrolling
Updated:  12/31/1969
Colorado Blood Cancer Institute
mi
from
Denver, CO
Phase 3 Study With Carfilzomib and Dexamethasone Versus Bortezomib and Dexamethasone for Relapsed Multiple Myeloma Patients
A Randomized, Open-label, Phase 3 Study of Carfilzomib Plus Dexamethasone vs. Bortezomib Plus Dexamethasone in Patients With Relapsed Multiple Myeloma
Status: Enrolling
Updated: 12/31/1969
Colorado Blood Cancer Institute
mi
from
Denver, CO
Click here to add this to my saved trials
Phase 3 Study With Carfilzomib and Dexamethasone Versus Bortezomib and Dexamethasone for Relapsed Multiple Myeloma Patients
A Randomized, Open-label, Phase 3 Study of Carfilzomib Plus Dexamethasone vs. Bortezomib Plus Dexamethasone in Patients With Relapsed Multiple Myeloma
Status: Enrolling
Updated:  12/31/1969
MAB Oncology/Hematology
mi
from
Melbourne, FL
Phase 3 Study With Carfilzomib and Dexamethasone Versus Bortezomib and Dexamethasone for Relapsed Multiple Myeloma Patients
A Randomized, Open-label, Phase 3 Study of Carfilzomib Plus Dexamethasone vs. Bortezomib Plus Dexamethasone in Patients With Relapsed Multiple Myeloma
Status: Enrolling
Updated: 12/31/1969
MAB Oncology/Hematology
mi
from
Melbourne, FL
Click here to add this to my saved trials
Phase 3 Study With Carfilzomib and Dexamethasone Versus Bortezomib and Dexamethasone for Relapsed Multiple Myeloma Patients
A Randomized, Open-label, Phase 3 Study of Carfilzomib Plus Dexamethasone vs. Bortezomib Plus Dexamethasone in Patients With Relapsed Multiple Myeloma
Status: Enrolling
Updated:  12/31/1969
Hematology Oncology of Indiana
mi
from
Indianapolis, IN
Phase 3 Study With Carfilzomib and Dexamethasone Versus Bortezomib and Dexamethasone for Relapsed Multiple Myeloma Patients
A Randomized, Open-label, Phase 3 Study of Carfilzomib Plus Dexamethasone vs. Bortezomib Plus Dexamethasone in Patients With Relapsed Multiple Myeloma
Status: Enrolling
Updated: 12/31/1969
Hematology Oncology of Indiana
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Phase 3 Study With Carfilzomib and Dexamethasone Versus Bortezomib and Dexamethasone for Relapsed Multiple Myeloma Patients
A Randomized, Open-label, Phase 3 Study of Carfilzomib Plus Dexamethasone vs. Bortezomib Plus Dexamethasone in Patients With Relapsed Multiple Myeloma
Status: Enrolling
Updated:  12/31/1969
Center for Cancer & Blood Disorders
mi
from
Bethesda, MD
Phase 3 Study With Carfilzomib and Dexamethasone Versus Bortezomib and Dexamethasone for Relapsed Multiple Myeloma Patients
A Randomized, Open-label, Phase 3 Study of Carfilzomib Plus Dexamethasone vs. Bortezomib Plus Dexamethasone in Patients With Relapsed Multiple Myeloma
Status: Enrolling
Updated: 12/31/1969
Center for Cancer & Blood Disorders
mi
from
Bethesda, MD
Click here to add this to my saved trials
Phase 3 Study With Carfilzomib and Dexamethasone Versus Bortezomib and Dexamethasone for Relapsed Multiple Myeloma Patients
A Randomized, Open-label, Phase 3 Study of Carfilzomib Plus Dexamethasone vs. Bortezomib Plus Dexamethasone in Patients With Relapsed Multiple Myeloma
Status: Enrolling
Updated:  12/31/1969
Associates in Oncology and Hematology
mi
from
Rockville, MD
Phase 3 Study With Carfilzomib and Dexamethasone Versus Bortezomib and Dexamethasone for Relapsed Multiple Myeloma Patients
A Randomized, Open-label, Phase 3 Study of Carfilzomib Plus Dexamethasone vs. Bortezomib Plus Dexamethasone in Patients With Relapsed Multiple Myeloma
Status: Enrolling
Updated: 12/31/1969
Associates in Oncology and Hematology
mi
from
Rockville, MD
Click here to add this to my saved trials
Phase 3 Study With Carfilzomib and Dexamethasone Versus Bortezomib and Dexamethasone for Relapsed Multiple Myeloma Patients
A Randomized, Open-label, Phase 3 Study of Carfilzomib Plus Dexamethasone vs. Bortezomib Plus Dexamethasone in Patients With Relapsed Multiple Myeloma
Status: Enrolling
Updated:  12/31/1969
University of Michigan
mi
from
Ann Arbor, MI
Phase 3 Study With Carfilzomib and Dexamethasone Versus Bortezomib and Dexamethasone for Relapsed Multiple Myeloma Patients
A Randomized, Open-label, Phase 3 Study of Carfilzomib Plus Dexamethasone vs. Bortezomib Plus Dexamethasone in Patients With Relapsed Multiple Myeloma
Status: Enrolling
Updated: 12/31/1969
University of Michigan
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Phase 3 Study With Carfilzomib and Dexamethasone Versus Bortezomib and Dexamethasone for Relapsed Multiple Myeloma Patients
A Randomized, Open-label, Phase 3 Study of Carfilzomib Plus Dexamethasone vs. Bortezomib Plus Dexamethasone in Patients With Relapsed Multiple Myeloma
Status: Enrolling
Updated:  12/31/1969
University of Kansas
mi
from
Kansas City, MO
Phase 3 Study With Carfilzomib and Dexamethasone Versus Bortezomib and Dexamethasone for Relapsed Multiple Myeloma Patients
A Randomized, Open-label, Phase 3 Study of Carfilzomib Plus Dexamethasone vs. Bortezomib Plus Dexamethasone in Patients With Relapsed Multiple Myeloma
Status: Enrolling
Updated: 12/31/1969
University of Kansas
mi
from
Kansas City, MO
Click here to add this to my saved trials
Phase 3 Study With Carfilzomib and Dexamethasone Versus Bortezomib and Dexamethasone for Relapsed Multiple Myeloma Patients
A Randomized, Open-label, Phase 3 Study of Carfilzomib Plus Dexamethasone vs. Bortezomib Plus Dexamethasone in Patients With Relapsed Multiple Myeloma
Status: Enrolling
Updated:  12/31/1969
Hackensack University Medical Center
mi
from
Hackensack, NJ
Phase 3 Study With Carfilzomib and Dexamethasone Versus Bortezomib and Dexamethasone for Relapsed Multiple Myeloma Patients
A Randomized, Open-label, Phase 3 Study of Carfilzomib Plus Dexamethasone vs. Bortezomib Plus Dexamethasone in Patients With Relapsed Multiple Myeloma
Status: Enrolling
Updated: 12/31/1969
Hackensack University Medical Center
mi
from
Hackensack, NJ
Click here to add this to my saved trials
Phase 3 Study With Carfilzomib and Dexamethasone Versus Bortezomib and Dexamethasone for Relapsed Multiple Myeloma Patients
A Randomized, Open-label, Phase 3 Study of Carfilzomib Plus Dexamethasone vs. Bortezomib Plus Dexamethasone in Patients With Relapsed Multiple Myeloma
Status: Enrolling
Updated:  12/31/1969
Montefiore Medical Center
mi
from
Bronx, NY
Phase 3 Study With Carfilzomib and Dexamethasone Versus Bortezomib and Dexamethasone for Relapsed Multiple Myeloma Patients
A Randomized, Open-label, Phase 3 Study of Carfilzomib Plus Dexamethasone vs. Bortezomib Plus Dexamethasone in Patients With Relapsed Multiple Myeloma
Status: Enrolling
Updated: 12/31/1969
Montefiore Medical Center
mi
from
Bronx, NY
Click here to add this to my saved trials
Phase 3 Study With Carfilzomib and Dexamethasone Versus Bortezomib and Dexamethasone for Relapsed Multiple Myeloma Patients
A Randomized, Open-label, Phase 3 Study of Carfilzomib Plus Dexamethasone vs. Bortezomib Plus Dexamethasone in Patients With Relapsed Multiple Myeloma
Status: Enrolling
Updated:  12/31/1969
Clinical Research Alliance
mi
from
New York, NY
Phase 3 Study With Carfilzomib and Dexamethasone Versus Bortezomib and Dexamethasone for Relapsed Multiple Myeloma Patients
A Randomized, Open-label, Phase 3 Study of Carfilzomib Plus Dexamethasone vs. Bortezomib Plus Dexamethasone in Patients With Relapsed Multiple Myeloma
Status: Enrolling
Updated: 12/31/1969
Clinical Research Alliance
mi
from
New York, NY
Click here to add this to my saved trials
Phase 3 Study With Carfilzomib and Dexamethasone Versus Bortezomib and Dexamethasone for Relapsed Multiple Myeloma Patients
A Randomized, Open-label, Phase 3 Study of Carfilzomib Plus Dexamethasone vs. Bortezomib Plus Dexamethasone in Patients With Relapsed Multiple Myeloma
Status: Enrolling
Updated:  12/31/1969
Gabrail Cancer Center
mi
from
Canton, OH
Phase 3 Study With Carfilzomib and Dexamethasone Versus Bortezomib and Dexamethasone for Relapsed Multiple Myeloma Patients
A Randomized, Open-label, Phase 3 Study of Carfilzomib Plus Dexamethasone vs. Bortezomib Plus Dexamethasone in Patients With Relapsed Multiple Myeloma
Status: Enrolling
Updated: 12/31/1969
Gabrail Cancer Center
mi
from
Canton, OH
Click here to add this to my saved trials
Phase 3 Study With Carfilzomib and Dexamethasone Versus Bortezomib and Dexamethasone for Relapsed Multiple Myeloma Patients
A Randomized, Open-label, Phase 3 Study of Carfilzomib Plus Dexamethasone vs. Bortezomib Plus Dexamethasone in Patients With Relapsed Multiple Myeloma
Status: Enrolling
Updated:  12/31/1969
The Christ Hospital
mi
from
Cincinnati, OH
Phase 3 Study With Carfilzomib and Dexamethasone Versus Bortezomib and Dexamethasone for Relapsed Multiple Myeloma Patients
A Randomized, Open-label, Phase 3 Study of Carfilzomib Plus Dexamethasone vs. Bortezomib Plus Dexamethasone in Patients With Relapsed Multiple Myeloma
Status: Enrolling
Updated: 12/31/1969
The Christ Hospital
mi
from
Cincinnati, OH
Click here to add this to my saved trials